雌激素受体不同表达对局部晚期乳腺癌TC化疗方案的敏感性观察  

Association Between Different ER Expression and the Sensitivity of TC Chemotherapy in Locally Advanced Breast Cancer Patients

作　　者：孙素红[1] 黄琴[1] 曾峰[1] 

机构地区：[1]遵义医学院附属医院,遵义市563003

出　　处：《中国药房》2009年第20期1558-1559,共2页China Pharmacy

摘　　要：目的:观察雌激素受体(ER)不同表达对局部晚期乳腺癌TC新辅助化疗方案的敏感性。方法:采用免疫组化EnVision法,检测57例局部晚期乳腺癌患者化疗前ER的表达情况,比较ER(-)病例与ER(+)病例对TC化疗方案的敏感性。结果:ER阴性组的敏感性为86.36%(19/22),ER阳性组的敏感性为60.00%(21/35),2组比较差异有统计学意义(P<0.05),说明ER(-)的乳腺癌患者对TC新辅助化疗方案更敏感。结论:ER(-)可作为局部晚期乳腺癌选用TC新辅助化疗方案的敏感性依据之一。OBJECTIVE： To observe the association between the ER expression and the sensitivity of TC chemotherapy in locally advanced breast cancer patients. METHODS： The expression of ER in 57 locally advanced breast cancer patients was detected by EnVision method, and the sensitivity to TC chemotherapy in ER negative （ - ）vs. ER positive （ ＋ ） patients were evaluated. RESULTS： There were significant differences between the ER negative （ - ） patients and the ER positive （ ＋ ） patients in the sensitivity to TC chemotherapy（86.36% （19/22） vs. 60.00% （21/35） ） （P （0.05）, demonstrating the higher sensitivity of ER negative（ - ） breast cancer patients to TC neoadjuvant chemotherapy. CONCLUSION： ER negative （ - ） may serve as a sensitivity marker to TC neoadjuvant chemotherapy in locally advanced breast cancer patients.

关 键 词：乳腺癌 新辅助化疗 疗效 雌激素受体 

分 类 号：R962[医药卫生—药理学] R969.4[医药卫生—药学]